Medicare Obesity Drug Coverage Starts July 1: What Seniors Must Know
A landmark Medicare coverage expansion for obesity drugs kicks off July 1, but many seniors remain in the dark about the benefit.
If you're on Medicare and you've been paying out of pocket for GLP-1 drugs like Wegovy or Zepbound, your wallet is about to get some relief. Starting July 1, Medicare is rolling out coverage for obesity medications — and it's a genuinely big deal for millions of seniors who've been priced out of these treatments.
Here's the catch: most seniors don't know it's happening. Neither the government nor the drugmakers — think Eli Lilly and Novo Nordisk — have run major advertising campaigns to spread the word. That's a stunning gap when you consider how transformative this coverage shift could be for people who qualify.
Read more SpaceX Is Already in Your 401(k) — OpenAI Could Be Next →
If you or someone you love is on Medicare, now is the time to get proactive. Don't wait for a mailer or a TV ad that may never come. Call your Medicare plan, talk to your doctor, and find out whether you're eligible to start accessing this benefit on day one. The drug costs aren't small, and coverage makes a massive difference.
From a tradeable angle, this quiet rollout is worth watching. Eli Lilly and Novo Nordisk both stand to see a meaningful demand surge from the Medicare population — a demographic that couldn't previously afford these drugs at scale. If uptake accelerates faster than expected, that's a catalyst neither stock has fully priced in yet.
Bottom line: this is a landmark policy moment buried under a lack of awareness. Seniors, your coverage is changing. Act now, not later. Continue reading at US Top News and Analysis.
